Publications and Posters
Publications
-
January 26, 2024
Preclinical dose response study shows NR2E3 can attenuate retinal degeneration in the retinitis pigmentosa mouse model RhoP23H+/−
June 1, 2023Drag S, Dotiwala F, Upadhyay AK. Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions. Invest Ophthalmol Vis Sci. Jun 1 2023;64(7):39. doi:10.1167/iovs.64.7.39
March 2, 2020Li S, Datta S, Brabbit E, et al. Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. Gene Ther. May 2021;28(5):223-241. doi:10.1038/s41434-020-0134-z
May 5, 2016Olivares AM, Moreno-Ramos OA, Haider NB. Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases. J Exp Neurosci. 2015;9(Suppl 2):93-121. doi:10.4137/JEN.S25480
July 22, 2009Schorderet DF, Escher P. NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP). Hum Mutat. Nov 2009;30(11):1475-85. doi:10.1002/humu.21096
March 19, 2008Haider NB, Zhang W, Hurd R, et al. Mapping of genetic modifiers of Nr2e3 rd7/rd7 that suppress retinal degeneration and restore blue cone cells to normal quantity. Mamm Genome. Mar 2008;19(3):145-54. doi:10.1007/s00335-008-9092-2
January 30, 2007Haider NB, Demarco P, Nystuen A, et al. The transcription factor Nr2e3 functions in retinal progenitors to suppress cone cell generation. Visual Neuroscience. 2006;23(6):917-929. doi:10.1017/S095252380623027X10-14
July 25, 2006Cheng H, Aleman TS, Cideciyan AV, Khanna R, Jacobson SG, Swaroop A. In vivo function of the orphan nuclear receptor NR2E3 in establishing photoreceptor identity during mammalian retinal development. Human Molecular Genetics. 2006;15(17):2588-2602. doi:10.1093/hmg/ddl185
-
May 16, 2024
Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD | Gene Therapy (springer.com)
December 5, 2023Rajanala K, Dotiwala F, Upadhyay A. Geographic atrophy: pathophysiology and current therapeutic strategies. Review. Frontiers in Ophthalmology. 2023-December-05 2023;3doi:10.3389/fopht.2023.1327883
October 6, 2011Jun G, Nicolaou M, Morrison MA, et al. Influence of ROBO1 and RORA on risk of age-related macular degeneration reveals genetically distinct phenotypes in disease pathophysiology. PLoS One. 2011;6(10):e25775. doi:10.1371/journal.pone.0025775
-
November 6, 2017
Patel PJ, Devonport H, Sivaprasad S, et al. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol. 2017;11:1957-1966. doi:10.2147/OPTH.S145732
January 18, 2017Silva RLE, Kanan Y, Mirando AC, et al. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Sci Transl Med. Jan 18 2017;9(373)doi:10.1126/scitranslmed.aai8030
May 1, 2016Gunda V, Sudhakar YA. Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors. J Cancer Sci Ther. Jul 4 2013;5(12):417-426. doi:10.4172/1948-5956.1000235
Venugopal Gunda and Yakkanti A Sudhakar. Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors. J Cancer Sci Ther.;5(12): 417-426.
-
October 12, 2023
Dotiwala F, Upadhyay AK. Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens. Vaccines. 2023;11(10):1585.
September 13, 2022Dotiwala F, Upadhyay AK. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. Review. Frontiers in Immunology. 2022-September-13 2022;13doi:10.3389/fimmu.2022.940715
Posters
-
June 14, 2024
OCU400 Poster